Recognizing & Treating Alpha-1 Antitrypsin Deficiency (AATD) - a podcast by ReachMD

CME credits: 1.00

Valid until: 24-08-2022

Claim your CME credit at https://reachmd.com/programs/cme/recognizing-and-treating-alpha-1-antitrypsin-deficiency-aatd/12765/

Alpha-1 antitrypsin deficiency (AATD) is a common yet underdiagnosed genetic disorder. Led by 2 AATD experts, this activity will address the most current information on the screening, diagnosis, and treatment of this potentially fatal disorder. AATD primarily affects the lungs and liver and requires a multidisciplinary care approach. Faculty will review patients who are at risk for AATD, its clinical manifestations (including similarities with COPD), and possible consequences to the lung and liver. Current treatment involves augmentation therapy with IV administration of AAT; there are ongoing investigations into other potential treatments. Patient cases will help clinicians apply the foundational information to clinical practice.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD